GLAXO.BO GL

GLAXO.BO GlaxoSmithKline Pharmaceuticals Limited

Healthcare · Drug Manufacturers - General

2 · Debole Momentum 6.7 · Neutrale Da monitorare

2649.00

-0.77%

Informazioni sull'azienda

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of herpes zoster and post-herpetic neuralgia. It also provides specialty medicines, such as NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and Trelegy Ellipta for treating chronic obstructive pulmonary disease. In addition, the company offers general medicines, including AUGMENTIN and CEFTUM, an oral antibiotic to treat bacterial infections; CobadexCZS to treat mineral and vitamins deficiency states in adult patients; Flutivate, a skin cream for adults, children and infants; Tenovate to treat inflammatory and pruritic manifestations of steroid responsive dermatosis; CALPOL to treat mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment of specific bacterial skin infections; BETNOVATE for skin conditions; T-BACT for bacterial skin infections; and PHYSIOGEL for dry skin associated with redness and itch. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is based in Mumbai, India.

2.15% previsto
84.22%
57.00
448.8B
39.14
67.68
2524.35

Intervallo 52 settimane

2649
min 2088 max 3121
Rendimento Crescita Momentum Sicurezza Valore Salute

Analisi approfondita del dividendo

GlaxoSmithKline Pharmaceuticals Limited (GLAXO.BO), a Drug Manufacturers - General company in the Healthcare sector, currently offers a dividend yield of 2.15%. Its dividend safety status is rated as "watch." The company has a momentum score of 6.7 on a 0-10 scale, indicating a positive recent price trend. However, specific value metrics to assess whether the stock is cheap or rich, and its current yield compared to its historical 5-year range, are not provided in the data.

Storico dei dividendi

Specific historical data regarding GlaxoSmithKline Pharmaceuticals Limited's dividend growth and consistency is not provided. The dividend history object is empty, and there is no information available on a dividend streak in years. Likewise, the 3-year and 5-year compound annual growth rates (CAGRs) for the dividend are not available in the provided data. The company's current annual dividend payment is 57.0 INR. Without this historical context, assessing the long-term trend or consistency of its dividend payments is not possible from the given information.

Sicurezza del dividendo

GlaxoSmithKline Pharmaceuticals Limited's dividend safety is rated as "watch." The company's payout ratio stands at 84.22% of its earnings per share, indicating that a substantial portion of earnings is allocated to dividends.

Quantic · Gratis

Leggi il resto sulla sicurezza del dividendo

In più i rischi principali e che cosa tenere d'occhio. Gratis, senza carta.

Generato dall'IA dai dati sui dividendi di Quantic · Aggiornato il 16 Nov 2026 · Informazioni, non consulenza finanziaria.

Mostrato in inglese — una traduzione è in arrivo.

Storico prezzi

2516 2516 2516 2026 2026-10 · 2516
Prezzo

Profilo del dividendo

Frequenza
—
Crescita (TTM)
—
CAGR 3a
—
—
—

Debito e leva finanziaria

2.1%
1.77
1.43
Debito vs liquidità
Debito Liquidità
Debito totale
357.1M INR
Liquidità totale
20.6B INR
11.9B INR

Ultimi dati di bilancio pubblicati.

Informazioni, non consulenza finanziaria.

Quantic · Gratis

Monitora GLAXO.BO e tutto il tuo portafoglio

Rendimento reale, sicurezza del dividendo, reddito netto d'imposta e il tuo percorso verso la libertà — gratis, senza connessione al broker.

€0

Ti serve di più? Pro aggiunge portafogli, monitoraggio del reddito da opzioni e più AI. Scopri Pro →